Nanobiotix S.A. (EPA: NANO)
4.984
+0.104 (2.13%)
Aug 30, 2024, 5:35 PM CET
Nanobiotix Revenue
In the fiscal year ending March 31, 2024, Nanobiotix had annual revenue of 402.01M EUR with 17.70% growth. Nanobiotix had revenue of 220.79M in the half year ending March 31, 2024, with 36.25% growth.
Revenue
402.01M
Revenue Growth
+17.70%
P/S Ratio
5.08
Revenue / Employee
354.98K
Employees
102
Market Cap
236.27M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 402.01M | 60.45M | 17.70% |
Mar 31, 2023 | 341.55M | 59.60M | 21.14% |
Mar 31, 2022 | 281.95M | 77.30M | 37.77% |
Mar 31, 2021 | 204.65M | -242.07M | -54.19% |
Mar 31, 2020 | 446.71M | 18.76M | 4.38% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
LVMH Moët Hennessy - Louis Vuitton, Société Européenne | 85.59B |
Hermès International Société en commandite par actions | 14.23B |
L'Oréal S.A. | 42.73B |
Schneider Electric S.E. | 36.44B |
Christian Dior SE | 85.59B |
EssilorLuxottica Société anonyme | 25.83B |
L'Air Liquide S.A. | 27.01B |
Nanobiotix News
- 2 months ago - NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024 - GlobeNewsWire
- 3 months ago - Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy - GlobeNewsWire
- 3 months ago - NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call - GlobeNewsWire
- 3 months ago - NANOBIOTIX to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 3 months ago - NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update - GlobeNewsWire
- 3 months ago - Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth - GlobeNewsWire
- 3 months ago - NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024 - GlobeNewsWire
- 3 months ago - NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer - GlobeNewsWire